An interventional study of Continuity-of-Care intervention in Diabetes Mellitus Type 2, sponsored by Institut Investigacio Sanitaria Pere Virgili. Active, not recruiting at 12 sites in Spain. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 18th largest by planned enrollment of the 383 interventional ones that give a count, is one of 18 that started in 2025, is one of 77 with no phase, reaches primary completion later than 14 of the 54 other live ones, and was the 399th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Spain, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 49 · Phase 3 209 · Phase 4 51
First in 2000; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,792 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 484 across the 383 interventional studies, 842 across the 46 observational. Of the 346 that completed or were terminated, 197 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
304 of 429 have an industry lead sponsor. The 10 most frequent:
Institut Investigacio Sanitaria Pere Virgili is the lead sponsor of 39 studies on the registry; 17 are open to participants now.
Institut Investigacio Sanitaria Pere Virgili has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 2 with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07269015Hospital Mutua de TerrassaCGM Accuracy in Pregnancy Study | 2026-12 |
| NCT06871059University of the Balearic IslandsEffectiveness, Implementation and Spillover Effects of a Culturally Adapted DPP in Spanish Primary Care Centers | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, parallel-group, cluster-randomized clinical trial evaluates the effectiveness of a continuity-of-care intervention to improve metabolic control in adults with type 2 diabetes mellitus (T2DM) in the Terres de l'Ebre health region. The intervention, led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta (HTVC), involves structured, multidisciplinary training and feedback provided by endocrinologists and nurse educators to primary care professionals. Training modules combine theoretical and practical content focused on current diabetes management.
Eleven primary care centers were randomized to intervention (n=5) or control (n=6) groups. Eligible participants are adult patients with an active diagnosis of T2DM for at least 12 months as of January 2025, registered in the eCAP system. Primary care professionals in intervention centers are offered the training intervention.
The intervention was conducted over one year (July 2025-July 2026). Quantitative data were collected at baseline, 6 months, and 12 months, with a further assessment planned at 24 months. The primary outcome is the between-group difference in mean HbA1c at 12 months, accounting for the cluster-randomized design. The 24-month assessment will evaluate the sustainability of the intervention effect. Six-month data are retained but are not included in the main effectiveness analysis.
Secondary outcomes include cardiovascular risk factors, diabetes complication screening, healthcare utilization, medication changes, and organizational variables. A qualitative component gathers professional input before and after the intervention to inform future implementation. Patient data are processed using appropriate confidentiality and data protection safeguards.
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic disease, accounting for approximately 90% of all diabetes cases, and is primarily managed in the primary care setting. The complexity of optimizing metabolic control in T2DM has increased, as current guidelines recommend a multifactorial approach that addresses not only glycemic control but also cardiovascular risk and multimorbidity. Glycated hemoglobin (HbA1c) remains a key marker for assessing glycemic control and the risk of diabetes-related complications.
Despite the availability of evidence-based clinical practice guidelines, their implementation in routine care is often suboptimal due to factors such as limited time, resources, clinical inertia, and challenges with patient adherence. Interventions targeting healthcare professionals and organizational processes, such as structured training, audit and feedback, and system-level changes, may improve metabolic outcomes.
This study is a parallel-group, cluster-randomized clinical trial designed to evaluate the effectiveness of a continuity-of-care intervention led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta (HTVC), in collaboration with primary care centers in the Terres de l'Ebre health region. Eleven primary care centers were randomized to the intervention (n=5) or control (n=6) group.
The intervention consists of structured, multidisciplinary training and feedback provided by endocrinologists and nurse educators to primary care physicians and nurses. Training sessions combine theoretical and practical content, focusing on current diabetes management strategies and the specific needs of each primary care center. The multidisciplinary team includes endocrinologists, diabetes nurse educators, and a specialist nurse from the Diabetic Foot Unit. Training was delivered onsite at intervention centers during scheduled sessions over a one-year period, from July 2025 to July 2026. Centers assigned to the control group continued usual care.
A qualitative component is integrated into the study, involving focus groups with primary care professionals before and after the intervention. This component aims to explore professional perspectives, identify barriers and facilitators, and inform future implementation of the intervention.
Quantitative data were collected at baseline (July 2025), 6 months, and 12 months (July 2026), with a further assessment planned at 24 months (July 2027). The primary outcome is the between-group difference in mean HbA1c at 12 months, analyzed according to the intention-to-treat principle and accounting for the cluster-randomized design. The 24-month assessment will evaluate the sustainability of the intervention effect. Six-month data are retained but will not be included in the main effectiveness analysis.
Secondary outcomes include cardiovascular risk factors, body mass index, smoking status, screening for diabetes-related complications, referrals to specialized care, emergency department visits, medication changes, and healthcare utilization.
Clinical data are obtained from electronic health records and processed in accordance with applicable data protection and confidentiality requirements.
This study aims to provide evidence on the effectiveness and sustainability of a multidisciplinary continuity-of-care intervention to improve metabolic control in adults with T2DM in a real-world primary care setting.
Protocol Amendment - Assessment Schedule and Data Extraction
The original protocol included quantitative assessments at baseline, 6, 12, and 24 months. During data quality review, it was identified that the electronic health record extraction labeled as the 12-month assessment contained data from the second six-month period rather than the complete first year of follow-up.
To reconstruct the first-year dataset, data from the 0-6-month and 6-12-month periods were combined. The 6-month data were retained, but the main effectiveness analysis was focused on the 12-month assessment, corresponding to the completion of the intervention, and the 24-month assessment, evaluating the sustainability of its effect.
This analytical decision was made before the investigators had access to the HbA1c results or between-group comparisons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Enrollment will begin in July 2025, aligned with the initiation of training sessions for healthcare professionals (physicians and nurses).
Eligible participants must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A parallel-group randomized clinical trial will be conducted in 11 primary care centers of the Terres de l'Ebre area (Catalan Health Institute). Randomization was performed by the data extractor before pseudonymization using simple randomization (1:1 ratio), generating values 0 and 1. Centers scoring \<0.5 were assigned to the control group; those ≥0.5 to the intervention group, resulting in 5 intervention and 6 control centers.
Other: Continuity-of-Care intervention
Primary care professionals provide care according to current local standard practices without receiving specific training on continuity-of-care strategies.
The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre. Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year. The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation.
Mean glycated hemoglobin (HbA1c) at 12 months
The primary outcome is the adjusted between-group difference in mean HbA1c at 12 months, comparing patients from primary care centers randomized to the intervention with those randomized to usual care. HbA1c will be analyzed as a continuous variable, expressed as a percentage, according to the intention-to-treat principle. The primary analysis will use a longitudinal linear mixed-effects model accounting for clustering within primary care centers and repeated measurements within patients.
Time frame: Baseline and 12 months after study start.
Change in total cholesterol and LDL cholesterol
Mean change in total and LDL cholesterol levels from baseline, measured in mg/dL.
Time frame: At baseline, 12 months, and 24 months after study start.
Change in systolic and diastolic blood pressure
Mean change in systolic and diastolic blood pressure from baseline, measured in mmHg.
Time frame: At baseline, 12 months, and 24 months after study start.
Change in smoking status
Change in smoking status (current, former, never) and number of cigarettes smoked per day.
Time frame: At baseline, 12 months, and 24 months after study start.
Change in Body Mass Index (BMI)
Mean change in BMI (Kg/m2) from baseline. BMI will be calculated as weight in kilograms divided by height in meters squared.
Time frame: At baseline, 12 months, and 24 months after study start.
Percentage of participants adherent to screening protocol for T2DM complications
Percentage of participants who complete all recommended screenings for chronic complications of T2DM, including screening for retinopathy, nephropathy, foot examination, and cardiovascular assessment.
Time frame: At baseline, 12 months, and 24 months after study start.
Referrals to the Diabetic Foot Unit
Evaluate the association between attendance at diabetic foot training and referrals to the Diabetic Foot Unit.
Time frame: At baseline, 12 months, and 24 months after study start.
Emergency assistance for metabolic decompensations
Evaluate whether patients present to emergency care with a diagnosis of metabolism and nutrition disorder according to CIE-10 ( CIE-10 E00-E90)
Time frame: At baseline, 12 months, and 24 months after study start.
Number of hospital referrals from primary care
Evaluate the number of hospital referrals to endocrinology specialty consultation after primary care attendance.
Time frame: At baseline, 12 months, and 24 months after study start.
Medication changes
Assess the association between professional attendance at training and medication changes.
Time frame: At baseline, 12 months, and 24 months after study start.
Number of patient visits to primary care
Evaluate the number of patient visits to primary care, stratified by nursing and physician attendance.
Time frame: At baseline, 12 months, and 24 months after study start.
Professional perceptions of relevance, feasibility and impact of the Continuity-of-Care intervention
Professional perceptions of the Continuity-of-Care intervention will be assessed through pre- and post-intervention focus groups. Focus groups will be conducted with professionals from different disciplines (primary care doctors and nurses). Transcripts will be analyzed using thematic content analysis to assess perceptions of relevance, feasibility, and impact of the intervention.
Time frame: Pre-intervention and 1 month post-intervention
Professional experiences with implementing the Continuity-of-Care intervention, including perceived barriers and facilitators
Professional experiences with implementing the Continuity-of-Care intervention will be assessed through pre- and post-intervention focus groups. Focus groups will be conducted with professionals from different disciplines (primary care doctors and nurses). Transcripts will be analyzed using thematic content analysis to assess experiences related to implementation and perceived barriers/facilitators.
Time frame: Pre-intervention and 1 month post-intervention.
Mean glycated hemoglobin (HbA1c) at 24 months
The secondary outcome is the adjusted between-group difference in mean HbA1c at 24 months, comparing patients from primary care centers randomized to the intervention with those randomized to usual care. This assessment will evaluate the sustainability of the intervention effect one year after its completion. The analysis will account for clustering within primary care centers and repeated measurements within patients.
Time frame: Baseline and 24 months after study start.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be upon request directly to the Principal Investigator.
Ran from Jul 2025 to primary completion in Jul 2026, 12 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 12 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jul 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Investigacio Sanitaria Pere Virgili